BioSpace News Archive

At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference.

Neurodegenerative disease refers to a range of partly inherited conditions that destroy the neurons in the human brain due to the progressive damage of the nerve cells caused by diseases.

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2022 first quarter results for Wednesday, May 4, 2022 before the market opens.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a summary of clinical and preclinical data reviewed during the American Association of Cancer Research (AACR) Annual Meeting.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 28,900 shares of the Company’s common stock at an exercise price per share of $33.70, which was the closing price on April 8, 2022, and restricted stock units to acquire a total of 14,450 shares of the Company’s common stock.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase) at the 2022 AACR Annual Meeting.

NANOBOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced new data from an open-label preclinical study evaluating the combination of first-in-class radioenhancer, NBTXR3, with the triple blockade of PD-1, LAG-3, and TIGIT (“Combination therapy”).

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, plans to release its first quarter 2022 results after the financial markets close on Wednesday, May 4, 2022.

Jerusalem, Israel and Boca Raton, Florida--(Newsfile Corp. - April 11, 2022) - NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned, Israel-based NewStem Ltd., today announced NewStem’s filing of a pre-submission to the FDA for a De Novo Request and an in vitro diagnostic device (IVDD) for Europe, the Middle East and Africa (EMA) for their NewStem Software Diagnostic Device.

Conformis, Inc. (NASDAQ: CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022, before the market opens on Wednesday, May 4, 2022, at approximately 7:00 a.m. Eastern Time.